FT Vest Laddered Autocallable Barrier & Income ETF

ACYN · ETF

$20.68−$0.04 (−0.19%)TodayMarket closed ·
Prev close $20.72

About ACYN

ACYN was created on 2026-02-24 by First Trust. The fund's investment portfolio concentrates primarily on income alternatives. ACYN is an actively managed ETF that uses swaps to synthetically invest in a laddered portfolio of autocallable notes referencing one or more US broad-based index. The fund aims for income with limited downside cushion.

Issuer
First Trust
Expense ratio
0.75%
Assets under management
$2.54B
Inception
Feb 24, 2026
Asset class
Alternatives

ACYN key statistics

Price-earnings ratio
0.00
Average volume
2.55M
Volume
2.28M
Open price
$20.65
High today
$20.68
Low today
$20.59
52 Week high
$21.87
52 Week low
$19.88

FT Vest Laddered Autocallable Barrier & Income ETF (ACYN) at a glance

FT Vest Laddered Autocallable Barrier & Income ETF (ACYN) last traded at $20.68, with a price-to-earnings ratio of 0.00.

Today the fund has traded between $20.59 and $20.68. The current price is 0.4% above the day's low and 0.0% below its high.

Volume so far is 2.28M shares, in line with the average of 2.55M shares a day.

Over the past year FT Vest Laddered Autocallable Barrier & Income ETF has ranged from $19.88 to $21.87, and now sits 40% of the way up that range.

ACYN news

  • Chandrima Sanyal

    Happy Birthday, Autocallable ETFs: Wall Street's Quiet Income Trade Has Already Raked In $2.5 Billion

  • Press releaseBusiness Wire

    First Trust Premiers Its First Laddered Autocallable Barrier & Income ETF

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.